Formulary
Almotriptan: Indications, Dosing, Side Effects and Interactions
Almotriptan clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Almotriptan: Indications, Dosing, Side Effects and Interactions
Almotriptan clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**Treatment of acute migraine**
- **Adult** (By Mouth): 12.5 mg, dose to be taken as soon as possible after onset, followed by 12.5 mg after 2 hours if required, dose to be taken only if migraine recurs (patient not responding to initial dose should not take second dose for same attack); maximum 25 mg per day.
Cautions
Conditions which predispose to coronary artery disease; elderly
Contraindications
Coronary vasospasm; ischaemic heart disease; peripheral vascular disease; previous cerebrovascular accident; previous myocardial infarction; previous transient ischaemic attack; Prinzmetal's angina; severe hypertension; uncontrolled hypertension
Side effects
Common or very common Asthenia; dizziness; drowsiness; nausea; vomiting Uncommon Bone pain; chest pain; diarrhoea; dry mouth; dyspepsia; headache; myalgia; palpitations; paraesthesia; throat tightness; tinnitus Rare or very rare Coronary vasospasm; myocardial infarction; tachycardia Frequency not known Intestinal ischaemia; seizure; vision disorders Side-effects, further information Discontinue if symptoms of heat, heaviness, pressure or tightness (including throat and chest) occur.
Interactions
**Other interactions (5):**
- Interaction studies were performed with monoamine oxidase A inhibitors, beta-blockers, selective serotonin re-uptake inhibitors, calcium channel blockers or inhibitors of Cytochrome P450 isoenzymes...
- There are no in vivo interaction studies assessing the effect of almotriptan on other drugs.
- Multiple dosing with the calcium channel blocker verapamil, a substrate of CYP3A4, resulted in a 20% increase in C max and AUC of almotriptan.
- Multiple dosing with propranolol did not alter the pharmacokinetics of almotriptan.
- In vitro studies performed to evaluate the ability of almotriptan to inhibit the major CYP enzymes in human liver microsomes and human monoamine oxidase (MAO) showed that almotriptan would not be...
Pregnancy
There is limited experience of using 5HT 1 -receptor agonists during pregnancy; manufacturers advise that they should be avoided unless the potential benefit outweighs the risk.
Breast feeding
Present in milk in animal studies-withhold breast-feeding for 24 hours.
Hepatic impairment
Manufacturer advises caution in mild to moderate impairment; avoid in severe impairment-no information available.
Renal impairment
Dose adjustments Max. 12.5 mg in 24 hours if creatinine clearance less than 30 mL/minute. M See Prescribing in renal impairment .
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Almotriptan in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

